Outcome of Board Meeting

September 11, 2026 The Listing Department, The Corporate Relations Department, National Stock Exchange of India Limited BSE Limited NSE Symbol: VIJAYA BSE Scrip Code: 543350 Dear Sir/Madam, Subject: Outcome of Board Meeting held on Friday, September 11, 2026 Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) as amended from time to time. We hereby inform you that, the Board of Directors of the Company at their meeting held today i.e., on Friday, September 11, 2026, has, inter-alia, considered and approved the acquisition of the integrated diagnostic business undertaking of Arya Wellness Centre, on a slump sale basis, from NEMRIL HRPL JV (North Eastern Medical Research Institute Limited – Hexagon Research Private Limited JV), subject to the terms and conditions set out in the Business Transfer Agreement (“BTA”). The detailed disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026 is enclosed as Annexure-A. The Board Meeting commenced at 05:45 p.m. and concluded at 06:05 p.m. Kindly take the same on record. Thanking You. Yours Faithfully For Vijaya Diagnostic Centre Limited Narasimha Raju K A Chief Financial Officer Encl.: as above Annexure–A Disclosures under Regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026 Sr. Particulars / Disclosure Details / Disclosures No. Requirement Target Business Undertaking: Acquisition of the integrated diagnostic business undertaking of Arya Wellness Centre on a slump Name of the target entity, sale basis from NEMRIL HRPL JV (North Eastern 1. details in brief such as size, Medical Research Institute Limited – Hexagon turnover etc. Research Private Limited JV). Turnover/Size: The turnover of the target business for the preceding financial year (FY 2025-26) was ₹ 26.95 Crores. Whether the acquisition would fall within related party transaction(s) and The proposed transaction does not constitute a related whether the promoter/ party transaction. The promoter, promoter group, and promoter group/ group group companies of the Company do not hold any 2. companies have any interest interest in the seller entity. Consequently, the in the entity being acquired? requirement of an arm's length assessment is not If yes, nature of interest and applicable. details thereof and whether the same is done at “arm's length”. Industry to which the The target business undertaking operates within the 3. entity/business being Healthcare and Diagnostics industry. acquired belongs. Objects and impact of acquisition (including but The acquisition is aligned with the Company’s not limited to, disclosure of strategic objective of expanding its diagnostic 4. reasons for acquisition of business into Assam and strengthening its presence in target entity, if its business is North-East India. outside the main line of business of the listed entity). Sr. Particulars / Disclosure Details / Disclosures No. Requirement Brief details of any The consummation of the transaction remains subject governmental or regulatory 5. to requisite statutory and regulatory approvals from approvals required for the the relevant governmental authorities. acquisition. The transaction is tentatively expected to be Indicative time period for completed within 90 days, or such extended period as 6. completion of the may be mutually agreed upon by the parties, subject acquisition. to the fulfilment of customary conditions precedent specified in the Business Transfer Agreement (BTA). Consideration – whether cash consideration or share 7. Cash Consideration. swap or any other form and details of the same. A total lump-sum purchase consideration of ₹ 46.20 Cost of acquisition and/or Crores (Rupees Forty-Six Crores and Twenty Lakhs the price at which the 8. Only) is payable pursuant to the terms of the Business business/shares are Transfer Agreement, subject to customary closing acquired. working capital adjustments. Not applicable. The transaction entails the acquisition of a business Percentage of shareholding / undertaking on a slump sale basis as a going concern, 9. control acquired and / or rather than the acquisition of equity shares. Post- number of shares acquired. completion, the Company shall assume 100% operational control over the said business undertaking. The target is a B2C-focused integrated diagnostic Brief background of the business providing comprehensive pathology and entity acquired in terms of radiology services. products/line of business acquired, date of It maintains an operational presence in Guwahati, incorporation, history of last Assam, India. 3 years turnover, country in Historical Turnover (Last 3 Financial Years): which the acquired entity • FY 2025-26: ₹ 26.95 Crores has presence and any other significant information (in • FY 2024-25: ₹ 25.61 Crores brief). • FY 2023-24: ₹ 22.99 Crores